echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > J Clin Oncol: Imetelstat, a telomerase inhibitor, can effectively treat myelofibrosis!

    J Clin Oncol: Imetelstat, a telomerase inhibitor, can effectively treat myelofibrosis!

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The clinical prognosis of myelofibrosis patients with relapse or JAKi refractory (R/R) after treatment with Janus-related kinase inhibitor (JAKi) is poor, and the overall survival rate (OS) is only 13-16 months


    Imetelstat is a telomerase inhibitor Imetelstat is a telomerase inhibitor

    The test patients were randomly divided into groups and received Imetelstat 9.


    A: OS of all randomized patients; B: correlation between OS and myelofibrosis change or stability

    A: OS of all randomized patients; B: correlation between OS and myelofibrosis change or stability

    Study enrollment ended early, and patients receiving 4.


    At 24 weeks, the spleen remission rate and symptom remission rate were 10.


    All in all, in this phase II trial of two doses of Imetelstat, patients with bad-risk JAKi-R/R myelofibrosis can get clinically beneficial symptoms from Imetelstat 9.


    JAKi-R/R myelofibrosis patients with adverse risks can obtain clinically beneficial symptom relief from Imetelstat 9.


    Original source:

    John Mascarenhas, et al.


    Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.